NexMed Presents Clinical Data On Femprox for Treating Female Sexual Dysfunction; U.S. Phase I Results to be Presented at Leading Workshop on FSD

Business Wire, Oct 20, 1999

ROBBINSVILLE, N.J.,--(BUSINESS WIRE)--Oct. 20, 1999--

NexMed, Inc. (OTC-BB:NEXM) announced today that it will present its U.S. Phase I clinical data on the Femprox topical treatment for female sexual dysfunction ("FSD"), at Boston University School of Medicine's New Perspectives in the Management of Female Sexual Dysfunction, in Boston, October 22-24, 1999. The clinical trial was conducted at the Robert Wood Johnson Medical School in New Brunswick, NJ.

The Femprox cream incorporates alprostadil (prostaglandin E1), an off-patent vasodilator drug recognized for treating male erectile dysfunction ("ED"), commonly known as impotence, and NexMed's proprietary NexACT transdermal drug delivery system. The Company is also developing Alprox-TD, its proprietary topical formulation for treating ED.

The Phase I clinical trial showed statistically significant (p<.05), dose-related improvements in arousal, lubrication, engorgement, pleasure, and relaxation. The Femprox product is intended to improve vaginal secretions and thereby increase sexual arousal and pleasure during intercourse.

Dr. James L. Yeager, Vice-President for Research and Development, commented, "This event gathers the leading research and development professionals in the study of FSD. This condition is estimated to affect 47 million American women, including 75% post-menopausal and 25% pre-menopausal women. We are very encouraged by the positive results from our U.S. Phase I trial which focused on the dose safety and efficacy of the product. We are preparing to enter U.S. Phase II clinical studies to test the product in a larger number of FSD patients to further confirm these findings."

The Company recently announced that it raised $8.5 million in a private equity placement of its securities. NexMed is using these resources to advance its planned U.S. Phase II studies on the Alprox-TD and Femprox creams.

NexMed, Inc., an emerging international pharmaceutical and medical device company, is developing 1) Alprox-TD and Femprox, topically-applied treatments for male and female sexual dysfunction; and 2) Viratrol, a non-invasive, hand-held device for treating oral and genital herpes.

Alprox-TD, Femprox, NexACT and Viratrol are trademarks of NexMed, Inc.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that are outside the control of the Company and may individually or mutually impact the matters herein described, including but not limited to the impact of competing technology, raising money, product development, manufacturing, and timely regulatory approvals.